Table 1.
Baseline Characteristics of 40 Randomized Study Participants receiving Radiation Therapy for Head and Neck (H&N) Cancer
| CHARACTERISTIC | CELECOXIB ARM | PLACEBO ARM |
|---|---|---|
| Number of Participants (n) | 20 | 20 |
| Demographics | ||
| Mean Age in Years (minimum-maximum) | 53.2 (34–71) | 56.0 (36–69) |
| Male (n, %) | 17 (85%) | 15 (75%) |
| Race and Ethnicity (n, %) | ||
| White, non-Hispanic | 20 (100%) | 17 (85%) |
| White, Hispanic | 0 (0%) | 2 (10%) |
| Black, non-Hispanic | 0 (0%) | 1 (5%) |
| Enrollment Site (n, %) | ||
| UConn Health Center | 18 (90%) | 20 (100%) |
| Hartford Hospital | 2 (10%) | 0 (0%) |
| Cancer Treatment | ||
| Mean Radiation Dose to Primary Site in Centigray (SD) | 6873 (266.9) | 6857 (270.9) |
| Bilateral radiation dosing (n, %) | 16 (80%) | 17 (85%) |
| Concomitant Chemotherapy (n, %) | 17 (85%) | 15 (75%) |
| Received surgery before radiation therapy | 9 (45%) | 10 (50%) |
| History of prior H&N radiation therapy | 1 (5%) | 0 (0%) |
| Primary Tumor Site by Category (n, %) | ||
| Oral cavity region | 5 (25%) | 6 (30%) |
| Soft palate/nasopharynx/tonsillar region | 6 (30%) | 4 (20%) |
| Pharynx and adjacent | 5 (25%) | 5 (25%) |
| Larynx and neck | 4 (20%) | 5 (25%) |
| H&N Cancer Stage (n, %) | ||
| I | 1 (5%) | 1 (5%) |
| II | 2 (10%) | 3 (15%) |
| III | 5 (25%) | 8 (40%) |
| IV | 12 (60%) | 8 (40%) |